94 related articles for article (PubMed ID: 12813632)
1. The role of radiotherapy in multimodal treatment of pancreatic carcinoma.
Brunner TB; Scott-Brown M
Radiat Oncol; 2010 Jul; 5():64. PubMed ID: 20615227
[TBL] [Abstract][Full Text] [Related]
2. A commentary on 'Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study'.
Zhong F; Xieb C; Peng X; Luo J; Yang H
Int J Surg; 2024 Mar; 110(3):1331-1332. PubMed ID: 38051933
[No Abstract] [Full Text] [Related]
3. Letter to the editor: Understanding surgical attrition for "resectable" pancreatic cancer.
Brown ZJ; Cloyd JM
HPB (Oxford); 2024 Apr; 26(4):606-607. PubMed ID: 38246826
[No Abstract] [Full Text] [Related]
4. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.
Joensuu TK; Kiviluoto T; Kärkkäinen P; Vento P; Kivisaari L; Tenhunen M; Westberg R; Elomaa I
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):444-52. PubMed ID: 15380578
[TBL] [Abstract][Full Text] [Related]
5. [Pancreatic carcinoma--overcome technically but not oncologically].
Herfarth Ch
Chirurg; 2003 Mar; 74(3):163-4. PubMed ID: 12722765
[No Abstract] [Full Text] [Related]
6. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Barhoumi M; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L; Chauffert B
Cancer Radiother; 2011 Jun; 15(3):182-91. PubMed ID: 21315644
[TBL] [Abstract][Full Text] [Related]
7. [Pancreatic cancer--diagnostics and therapy].
Schramm H
Zentralbl Chir; 2003 May; 128(5):367. PubMed ID: 12813632
[No Abstract] [Full Text] [Related]
8. [Chemoradiation for pancreatic adenocarcinoma].
Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
[TBL] [Abstract][Full Text] [Related]
9. Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Brown ZJ; Cloyd JM
J Surg Oncol; 2021 May; 123(6):1432-1440. PubMed ID: 33831253
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs in pancreatic cancer.
Ducreux M; Boige V; Malka D
Expert Opin Emerg Drugs; 2004 May; 9(1):73-89. PubMed ID: 15155137
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
